Achuta Kumar Guddati
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Achuta Kumar Guddati has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
Iuliana Shapira
Division of Hematology/Oncology, SUNY Downstate Medical Center, Brooklyn, NY, 11203, USA
7 shared publicationsGagan Kumar
Division of Internal Medicine Northeast Georgia Health System Gainesville Georgia USA
6 shared publications- Gagan Kumar
Northeast Georgia Health System, Atlanta, GA
6 shared publications Vamsi Kota
Augusta Univ, Georgia Canc Ctr, Div Hematol Oncol, Augusta, GA 30909 USA
6 shared publicationsJustin Yeh
Medical College of Georgia
5 shared publicationsHector Picon
Medical College of Georgia, Augusta University, Augusta, GA 30912
4 shared publications
Latest Publications
- 11 December 2025
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 40 (6) , e70078
A Simplified Scoring System to Predict In‐Hospital Mortality of Leukapheresis in Patients With Leukemia
The American Society for Apheresis recommends leukapheresis as a category II recommendation for symptomatic hyperleukocytosis. Mortality in these patients varies between 8%–29%. However, no tool is currently available to assess the mortality risk following the procedure. This study aims to assess the factors associated with in‐hospital mortality and develop a risk stratification tool consisting of clinically relevant variables to categorize patients based on their mortality risk following the procedure. The National Inpatient Sample Database (2016–2021) and ICD‐10 coding were utilized to identify adults with leukemia who underwent leukapheresis. Multivariate logistic regression models were constructed to identify independent factors of mortality. A scoring system was constructed to identify the risks of mortality using the variables in the model and their associated odds ratio (OR). The cumulative risk score was divided into three strata: low (mortality < 20%), intermediate (20%–50%), and high risk (> 50%). Of the estimated 3555 patients who underwent leukapheresis, 40.1% also received chemotherapy. Most patients who underwent leukapheresis had myeloid leukemia (52.2%), followed by lymphoid leukemia (14.2%), monocytic leukemia (6.2%), and the remaining were other types of leukemia. Variables incorporated into the scoring system include: monocytic leukemia, age over 50, morbid obesity, and interventions performed before leukapheresis, such as mechanical ventilation and blood transfusions. The cumulative mortality score ranged from 0 to 30, categorizing patients into high risk (score > 13), intermediate risk (6–13), and low risk (0–5). The risk score demonstrated a performance with an area under the curve of 0.82. A novel simplified scoring tool to predict in‐hospital mortality in leukemia patients requiring leukapheresis is presented here. This tool can assist in preprocedural risk assessment, help guide management planning, and consideration of other treatment modalities.
- 11 December 2025
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 40 (6) , e70078
A Simplified Scoring System to Predict In‐Hospital Mortality of Leukapheresis in Patients With Leukemia
The American Society for Apheresis recommends leukapheresis as a category II recommendation for symptomatic hyperleukocytosis. Mortality in these patients varies between 8%–29%. However, no tool is currently available to assess the mortality risk following the procedure. This study aims to assess the factors associated with in‐hospital mortality and develop a risk stratification tool consisting of clinically relevant variables to categorize patients based on their mortality risk following the procedure. The National Inpatient Sample Database (2016–2021) and ICD‐10 coding were utilized to identify adults with leukemia who underwent leukapheresis. Multivariate logistic regression models were constructed to identify independent factors of mortality. A scoring system was constructed to identify the risks of mortality using the variables in the model and their associated odds ratio (OR). The cumulative risk score was divided into three strata: low (mortality < 20%), intermediate (20%–50%), and high risk (> 50%). Of the estimated 3555 patients who underwent leukapheresis, 40.1% also received chemotherapy. Most patients who underwent leukapheresis had myeloid leukemia (52.2%), followed by lymphoid leukemia (14.2%), monocytic leukemia (6.2%), and the remaining were other types of leukemia. Variables incorporated into the scoring system include: monocytic leukemia, age over 50, morbid obesity, and interventions performed before leukapheresis, such as mechanical ventilation and blood transfusions. The cumulative mortality score ranged from 0 to 30, categorizing patients into high risk (score > 13), intermediate risk (6–13), and low risk (0–5). The risk score demonstrated a performance with an area under the curve of 0.82. A novel simplified scoring tool to predict in‐hospital mortality in leukemia patients requiring leukapheresis is presented here. This tool can assist in preprocedural risk assessment, help guide management planning, and consideration of other treatment modalities.
- Open Access
- 1 February 2023
- Published by Elmer Press, Inc. in World Journal of Oncology
- Vol. 14 (1) , 4-14
Carcinoembryonic Antigen, Carbohydrate Antigen 19-9, Cancer Antigen 125, Prostate-Specific Antigen and Other Cancer Markers: A Primer on Commonly Used Cancer Markers
Carcinoembryonic Antigen, Carbohydrate Antigen 19-9, Cancer Antigen 125, Prostate-Specific Antigen and Other Cancer Markers: A Primer on Commonly Used Cancer Markers
- 1 February 2023
- Published by Elmer Press, Inc. in World Journal of Oncology
- Vol. 14 (1) , 4-14
Open AccessCarcinoembryonic Antigen, Carbohydrate Antigen 19-9, Cancer Antigen 125, Prostate-Specific Antigen and Other Cancer Markers: A Primer on Commonly Used Cancer Markers
Carcinoembryonic Antigen, Carbohydrate Antigen 19-9, Cancer Antigen 125, Prostate-Specific Antigen and Other Cancer Markers: A Primer on Commonly Used Cancer Markers
- Open Access
- 1 December 2022
- Published by Elmer Press, Inc. in World Journal of Oncology
- Vol. 13 (6) , 329-336
Bimodal Age Distribution in Cancer Incidence
Bimodal Age Distribution in Cancer Incidence
- 1 December 2022
- Published by Elmer Press, Inc. in World Journal of Oncology
- Vol. 13 (6) , 329-336
Open AccessBimodal Age Distribution in Cancer Incidence
Bimodal Age Distribution in Cancer Incidence
- Open Access
- 1 April 2022
- Published by Wolters Kluwer Health in European Journal of Oncology Pharmacy
- Vol. 5 (2) , e00034
Cost-effectiveness analysis of pembrolizumab versus standard of care in recurrent or metastatic squamous cell carcinoma of the head and neck
Increasing costs of cancer treatment and anticancer drugs can create a financial burden on society and the individual. Pembrolizumab is an anti-PD-1 inhibitor immunotherapy approved for use in recurrent or metastatic head and neck squamous cell carcinoma. Limited data exists on the cost-effectiveness of pembrolizumab in this setting. This study compares the costeffectiveness of pembrolizumab against traditional chemotherapy using data from KEYNOTE-040. Published data from KEYNOTE-040 were used to create a model estimating treatment costs and overall survival benefit of pembrolizumab and traditional chemotherapy. Costs of treatment of toxicity-related events were obtained from previous literature and were incorporated into the model. Derivation of survival benefit gained from treatment was measured in quality-adjusted life-years (QALYs). The incremental cost-effectiveness ratio (ICER) of pembrolizumab compared to the investigator's choice (IC) was $801,864/QALY. The average drug cost of pembrolizumab would have to approximately decrease by 63% in order to reach the cost-effective threshold of $100,000/ QALY. Pembrolizumab would have to confer a survival benefit of 0.88 QALYs per patient over the IC to reach the cost-effective threshold. Pembrolizumab is not considered cost effective at a threshold of $100,000/QALY based on survival data reported in KEYNOTE-040. Improved long-term outcomes of patients on this relatively new immunotherapy have yet to be reported. Inclusion of these data in the future would likely improve the cost-effectiveness calculations of pembrolizumab and other immunotherapies.
- 1 April 2022
- Published by Wolters Kluwer Health in European Journal of Oncology Pharmacy
- Vol. 5 (2) , e00034
Open AccessCost-effectiveness analysis of pembrolizumab versus standard of care in recurrent or metastatic squamous cell carcinoma of the head and neck
Increasing costs of cancer treatment and anticancer drugs can create a financial burden on society and the individual. Pembrolizumab is an anti-PD-1 inhibitor immunotherapy approved for use in recurrent or metastatic head and neck squamous cell carcinoma. Limited data exists on the cost-effectiveness of pembrolizumab in this setting. This study compares the costeffectiveness of pembrolizumab against traditional chemotherapy using data from KEYNOTE-040. Published data from KEYNOTE-040 were used to create a model estimating treatment costs and overall survival benefit of pembrolizumab and traditional chemotherapy. Costs of treatment of toxicity-related events were obtained from previous literature and were incorporated into the model. Derivation of survival benefit gained from treatment was measured in quality-adjusted life-years (QALYs). The incremental cost-effectiveness ratio (ICER) of pembrolizumab compared to the investigator's choice (IC) was $801,864/QALY. The average drug cost of pembrolizumab would have to approximately decrease by 63% in order to reach the cost-effective threshold of $100,000/ QALY. Pembrolizumab would have to confer a survival benefit of 0.88 QALYs per patient over the IC to reach the cost-effective threshold. Pembrolizumab is not considered cost effective at a threshold of $100,000/QALY based on survival data reported in KEYNOTE-040. Improved long-term outcomes of patients on this relatively new immunotherapy have yet to be reported. Inclusion of these data in the future would likely improve the cost-effectiveness calculations of pembrolizumab and other immunotherapies.
- Open Access
- 1 April 2022
- Published by Elmer Press, Inc. in World Journal of Oncology
- Vol. 13 (2) , 96-101
Increasing Trends in Mortality Rate Among Salivary Gland Tumors in Non-Geriatric African Americans
Background: The treatment of salivary gland tumors has not changed significantly in the past two decades. However, the increase in the geriatric population with these tumors poses a new challenge for their management. This study explores the incidence-based mortality trends in the geriatric and non-geriatric population for the time period of 2000 - 2014 and compares the trends between races. Methods: Mortality data were extracted from the Surveillance, Epidemiology, and End Results (SEER) Database for the years 2000 - 2014. Incidence-based mortality for all stages of salivary gland tumors was queried and the results were grouped by age (geriatric vs. non-geriatric determined as 65 vs. below 65 years of age) and race (Caucasian/White, African American/Black, American Indian/Alaskan native and Asian/Pacific Islander). All stages and both genders were included in the analysis. T-test was used to determine statistically significant difference between various subgroups. Linearized trend lines were used to visualize the mortality trends between various subgroups (geriatric vs. non-geriatric and Caucasian vs. African American). Results: Incidence-based mortality for salivary gland tumors has worsened since 2000 to 2014 for both geriatric and non-geriatric patients (P < 0.05). There was a statistically significant difference between these two groups in both Caucasian/White patients and African American/Black patients. Notably, the worst incidence-based mortality rates were noted in African American/Black non-geriatric patients followed by Caucasian/White non-geriatric patients. However, there was no statistical difference in incidence-based mortality between Caucasian/White patients and African American/Black geriatric patients. Conclusions: The similarity in incidence-based mortality for geriatric patients with salivary gland tumors in both Caucasian/White patients and African American/Black groups suggests that the effects of race may not be pronounced in the elderly population. The high rate of incidence-based mortality in African American/Black non-geriatric patients may suggest environmental influence and warrants further study. World J Oncol. 2022;000(000):000-000 doi: https://doi.org/10.14740/wjon1420
- 1 April 2022
- Published by Elmer Press, Inc. in World Journal of Oncology
- Vol. 13 (2) , 96-101
Open AccessIncreasing Trends in Mortality Rate Among Salivary Gland Tumors in Non-Geriatric African Americans
Background: The treatment of salivary gland tumors has not changed significantly in the past two decades. However, the increase in the geriatric population with these tumors poses a new challenge for their management. This study explores the incidence-based mortality trends in the geriatric and non-geriatric population for the time period of 2000 - 2014 and compares the trends between races. Methods: Mortality data were extracted from the Surveillance, Epidemiology, and End Results (SEER) Database for the years 2000 - 2014. Incidence-based mortality for all stages of salivary gland tumors was queried and the results were grouped by age (geriatric vs. non-geriatric determined as 65 vs. below 65 years of age) and race (Caucasian/White, African American/Black, American Indian/Alaskan native and Asian/Pacific Islander). All stages and both genders were included in the analysis. T-test was used to determine statistically significant difference between various subgroups. Linearized trend lines were used to visualize the mortality trends between various subgroups (geriatric vs. non-geriatric and Caucasian vs. African American). Results: Incidence-based mortality for salivary gland tumors has worsened since 2000 to 2014 for both geriatric and non-geriatric patients (P < 0.05). There was a statistically significant difference between these two groups in both Caucasian/White patients and African American/Black patients. Notably, the worst incidence-based mortality rates were noted in African American/Black non-geriatric patients followed by Caucasian/White non-geriatric patients. However, there was no statistical difference in incidence-based mortality between Caucasian/White patients and African American/Black geriatric patients. Conclusions: The similarity in incidence-based mortality for geriatric patients with salivary gland tumors in both Caucasian/White patients and African American/Black groups suggests that the effects of race may not be pronounced in the elderly population. The high rate of incidence-based mortality in African American/Black non-geriatric patients may suggest environmental influence and warrants further study. World J Oncol. 2022;000(000):000-000 doi: https://doi.org/10.14740/wjon1420
- Open Access
- 1 February 2022
- Published by Elmer Press, Inc. in World Journal of Oncology
- Vol. 13 (1) , 8-19
Tumor Dormancy: Biologic and Therapeutic Implications
Tumor Dormancy: Biologic and Therapeutic Implications
- 1 February 2022
- Published by Elmer Press, Inc. in World Journal of Oncology
- Vol. 13 (1) , 8-19
Open AccessTumor Dormancy: Biologic and Therapeutic Implications
Tumor Dormancy: Biologic and Therapeutic Implications
- Open Access
- 1 February 2022
- Published by Elmer Press, Inc. in World Journal of Oncology
- Vol. 13 (1) , 1-7
Advances in the Treatment of Mucoepidermoid Carcinoma
Advances in the Treatment of Mucoepidermoid Carcinoma
- 1 February 2022
- Published by Elmer Press, Inc. in World Journal of Oncology
- Vol. 13 (1) , 1-7
Open AccessAdvances in the Treatment of Mucoepidermoid Carcinoma
Advances in the Treatment of Mucoepidermoid Carcinoma
- Open Access
- 1 December 2021
- Published by Elmer Press, Inc. in World Journal of Oncology
- Vol. 12 (6) , 225-231
Analysis of Demographics and Outcomes of Surgical Resection in the Central Nervous System of Patients With Metastatic Melanoma
Background: Patients with melanoma frequently develop central nervous system metastases. Oligometastatic disease is often treated either by surgical resection or by stereotactic radiotherapy. This study investigates the trends and clinical outcomes of patients with melanoma who have undergone surgical procedures on the central nervous system during their hospitalization. Methods: A retrospective study was performed based on admissions of adult patients who underwent craniotomy for metastatic melanoma from 2000 to 2014 using the Nationwide Inpatient Sample database. The primary outcome measure was all-cause in-hospital mortality. Secondary outcomes included hospital length of stay (LOS) and discharge disposition (home/home with health care and skilled nursing facilities/long-term acute care (SNFs/LTAC)). Factors associated with in-hospital mortality were examined by multivariable logistic regression. We adjusted for patient and hospital characteristics, payer, and comorbid conditions. We also examined trends of mortality for the study years. Results: There were an estimated 1,216 discharges of patients with melanoma undergoing craniotomy during the study period. Patients undergoing surgical interventions were typically males (69%) and whites (79%). Ninety-eight percent of procedures were performed at teaching hospitals. Unadjusted all-cause in-hospital mortality was 3.1%. There was no significant difference in mortality over 13 years. Age, gender, and race were not associated with increased in-hospital mortality. LOS was longer in elderly and those with higher Charlson Comorbidity Index. Of the survivors, 76% were discharged to home or with home healthcare while 24% were discharged to SNFs/LTAC. Patients with age > 65 (odds ratio (OR): 2.9; 95% confidence interval (CI): 2.2 - 3.9, P < 0.001) and those with higher Charlson Comorbidity Index (OR: 1.2; 95% CI: 1.1 - 1.3) had higher odds for being discharged to SNFs/LTAC. Conclusions: Patients who undergo craniotomy for metastatic melanoma have a low in-hospital mortality rate. One quarter of patients were discharged to SNFs/LTAC. World J Oncol. 2021;12(6):225-231 doi: https://doi.org/10.14740/wjon1408
- 1 December 2021
- Published by Elmer Press, Inc. in World Journal of Oncology
- Vol. 12 (6) , 225-231
Open AccessAnalysis of Demographics and Outcomes of Surgical Resection in the Central Nervous System of Patients With Metastatic Melanoma
Background: Patients with melanoma frequently develop central nervous system metastases. Oligometastatic disease is often treated either by surgical resection or by stereotactic radiotherapy. This study investigates the trends and clinical outcomes of patients with melanoma who have undergone surgical procedures on the central nervous system during their hospitalization. Methods: A retrospective study was performed based on admissions of adult patients who underwent craniotomy for metastatic melanoma from 2000 to 2014 using the Nationwide Inpatient Sample database. The primary outcome measure was all-cause in-hospital mortality. Secondary outcomes included hospital length of stay (LOS) and discharge disposition (home/home with health care and skilled nursing facilities/long-term acute care (SNFs/LTAC)). Factors associated with in-hospital mortality were examined by multivariable logistic regression. We adjusted for patient and hospital characteristics, payer, and comorbid conditions. We also examined trends of mortality for the study years. Results: There were an estimated 1,216 discharges of patients with melanoma undergoing craniotomy during the study period. Patients undergoing surgical interventions were typically males (69%) and whites (79%). Ninety-eight percent of procedures were performed at teaching hospitals. Unadjusted all-cause in-hospital mortality was 3.1%. There was no significant difference in mortality over 13 years. Age, gender, and race were not associated with increased in-hospital mortality. LOS was longer in elderly and those with higher Charlson Comorbidity Index. Of the survivors, 76% were discharged to home or with home healthcare while 24% were discharged to SNFs/LTAC. Patients with age > 65 (odds ratio (OR): 2.9; 95% confidence interval (CI): 2.2 - 3.9, P < 0.001) and those with higher Charlson Comorbidity Index (OR: 1.2; 95% CI: 1.1 - 1.3) had higher odds for being discharged to SNFs/LTAC. Conclusions: Patients who undergo craniotomy for metastatic melanoma have a low in-hospital mortality rate. One quarter of patients were discharged to SNFs/LTAC. World J Oncol. 2021;12(6):225-231 doi: https://doi.org/10.14740/wjon1408
- Open Access
- 1 December 2021
- Published by Elmer Press, Inc. in World Journal of Oncology
- Vol. 12 (6) , 195-205
Infections in Hospitalized Cancer Patients
Infections in Hospitalized Cancer Patients
- 1 December 2021
- Published by Elmer Press, Inc. in World Journal of Oncology
- Vol. 12 (6) , 195-205
Open AccessInfections in Hospitalized Cancer Patients
Infections in Hospitalized Cancer Patients
- Open Access
- 1 October 2021
- Published by Elmer Press, Inc. in World Journal of Oncology
- Vol. 12 (5) , 149-154
Genetic Polymorphisms in Pharmaceuticals and Chemotherapy
Genetic Polymorphisms in Pharmaceuticals and Chemotherapy
- 1 October 2021
- Published by Elmer Press, Inc. in World Journal of Oncology
- Vol. 12 (5) , 149-154
Open AccessGenetic Polymorphisms in Pharmaceuticals and Chemotherapy
Genetic Polymorphisms in Pharmaceuticals and Chemotherapy